4.4 Article

High-risk screening for Gaucher disease in patients with neurological symptoms

Journal

JOURNAL OF HUMAN GENETICS
Volume 63, Issue 6, Pages 717-721

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s10038-018-0438-7

Keywords

-

Funding

  1. Ministry of Health, Labor and Welfare of Japan
  2. Ministry of Education, Culture, Sports, Science and Technology
  3. Shire Pharmaceuticals

Ask authors/readers for more resources

Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by the deficiency of glucocerebrosidase enzyme activity. Clinical phenotypes of GD are categorized into three groups: (i) non-neuronopathic GD (type 1), (ii) acute neuronopathic GD (type 2) and (iii) subacute neuronopathic GD (type 3). The high-risk screening of neuronopathic GD has been performed using an enzymatic assay on the dried blood spot (DBS) samples. We enrolled a total of 102 individuals (47 females, 55 males; 0-57 years old; median age 10.5 years) with various neurological symptoms. We detected two patients with very low enzyme activity and they were diagnosed with the disease by using glucocerebrosidase gene analysis. Patient 1 was found to be compound heterozygous for the p.R159W/p.R170C locus and patient 2 was found to harbor two mutations at the IVS7+1G>T (c.999+1G>T) and p.L483P sites. This simple screening protocol using DBS samples is useful for early diagnosis of GD in high-risk and underdiagnosed patients suffering from various neurological symptoms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biotechnology & Applied Microbiology

A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II

Torayuki Okuyama, Yoshikatsu Eto, Norio Sakai, Kimitoshi Nakamura, Tatsuyoshi Yamamoto, Mariko Yamaoka, Toshiaki Ikeda, Sairei So, Kazunori Tanizawa, Hiroyuki Sonoda, Yuji Sato

Summary: The study demonstrated that pabinafusp alfa is a potentially effective treatment for both the central and peripheral symptoms of MPS-II patients, with the ability to cross the blood-brain barrier to reach the central nervous system. In the 52-week clinical trial, the drug showed relatively good efficacy and safety profiles.

MOLECULAR THERAPY (2021)

Article Pediatrics

Guide for diagnosis and treatment of hyperphenylalaninemia

Haruo Shintaku, Toshihiro Ohura, Masaki Takayanagi, Shigeo Kure, Misao Owada, Yoichi Matsubara, Makoto Yoshino, Yoshiyuki Okano, Tetsuya Ito, Torayuki Okuyama, Kimitoshi Nakamura, Masafumi Matuo, Fumio Endo, Hiroyuki Ida

Summary: The importance of sapropterin hydrochloride for the treatment of tetrahydrobiopterin-responsive hyperphenylalaninemia is highlighted, with recommendations to diagnose through tetrahydrobiopterin administration tests instead of relying on phenotype or blood phenylalanine levels. Treatment with sapropterin hydrochloride is feasible for all ages in cases of tetrahydrobiopterin-responsive hyperphenylalaninemia, and further investigation is needed despite reported efficacy and safety in preventing maternal phenylketonuria.

PEDIATRICS INTERNATIONAL (2021)

Article Clinical Neurology

Mitochondrial DNA depletion syndrome with a mutation in SLC25A4 developing epileptic encephalopathy: A case report

Tomoko Kashiki, Jun Kido, Ken Momosaki, Shouichirou Kusunoki, Shiro Ozasa, Keiko Nomura, Atsuko Imai-Okazaki, Tomoko Tsuruoka, Kei Murayama, Yasutoshi Koga, Kimitoshi Nakamura

Summary: MTDPS-12A is characterized by severe hypotonia from birth due to a mutation in ANT1, and status epilepticus could cause encephalopathy in these patients. Reduce energy requirement on cardiac muscle and brain may be a treatment strategy for MTDPS-12A patients. Seizure management and preventive treatment of status epilepticus are considered important for maintaining neurodevelopmental outcomes.

BRAIN & DEVELOPMENT (2022)

Article Endocrinology & Metabolism

Role of liver transplantation in urea cycle disorders: Report from a nationwide study in Japan

Jun Kido, Shirou Matsumoto, Johannes Haeberle, Yukihiro Inomata, Mureo Kasahara, Seisuke Sakamoto, Reiko Horikawa, Akihiro Tanemura, Hideaki Okajima, Tatsuya Suzuki, Kimitoshi Nakamura

Summary: Liver transplantation is effective for long-term survival and prevention of recurrent hyperammonemia in UCDs patients. However, it has limited effect on improving neurodevelopmental outcomes, especially for patients with severe disease, as hyperammonemia at the onset time can significantly impact the brain. Patients with ASSD may have a higher chance of survival without cognitive impairment if they receive early LT despite having severe neonatal hyperammonemia.

JOURNAL OF INHERITED METABOLIC DISEASE (2021)

Article Genetics & Heredity

Physical, cognitive, and social status of patients with urea cycle disorders in Japan

Jun Kido, Shirou Matsumoto, Tetsuya Ito, Shinichi Hirose, Kaori Fukui, Kanako Kojima-Ishii, Yuichi Mushimoto, Shinobu Yoshida, Mika Ishige, Norio Sakai, Kimitoshi Nakamura

Summary: Urea cycle disorders are inherited metabolic diseases that result in hyperammonemia and brain damage. A nationwide study in Japan from 2000 to 2018 provided insights into the diagnosis, treatments, and outcomes of UCD patients, revealing the impact on growth and social life of patients in Japan.

MOLECULAR GENETICS AND METABOLISM REPORTS (2021)

Article Transplantation

Complete Remission of Refractory Immunothrombocytopenic Purpura After Tacrolimus Replacement With Cyclosporine in a Case of Living Related Liver Transplant

Masayoshi Hamaguchi, Rieko Sakamoto, Kensaku Kohrogi, Takahiro Yamashita, Keishiro Furuie, Tadashi Anan, Kimitoshi Nakamura

Summary: Immuno-thrombocytopenic purpura is a potential complication after liver transplant, with therapy usually involving corticosteroids, intravenous immunoglobulin, and immunosuppressive drugs like cyclosporine and rituximab. Switching from tacrolimus to cyclosporine may lead to complete remission in some cases of intractable immuno-thrombocytopenic purpura.

EXPERIMENTAL AND CLINICAL TRANSPLANTATION (2021)

Article Endocrinology & Metabolism

Clinical manifestation and long-term outcome of citrin deficiency: Report from a nationwide study in Japan

Jun Kido, Johannes Haberle, Keishin Sugawara, Toju Tanaka, Masayoshi Nagao, Takaaki Sawada, Yoichi Wada, Chikahiko Numakura, Kei Murayama, Yoriko Watanabe, Kanako Kojima-Ishii, Hideo Sasai, Kiyotaka Kosugiyama, Kimitoshi Nakamura

Summary: This study investigates the clinical manifestations, medical therapy, and long-term outcome in 222 Japanese patients with citrin deficiency. The results show that patients with citrin deficiency have an increased risk for low weight and length at birth, and citrullinemia patients have an increased risk for growth impairment during adolescence. Liver transplantation has shown positive outcomes in a small number of patients.

JOURNAL OF INHERITED METABOLIC DISEASE (2022)

Article Pediatrics

Procalcitonin is associated with postnatal respiratory condition severity in preterm neonate

Masanori Iwai, Hidetaka Yoshimatsu, Tetsuo Naramura, Hiroko Imamura, Tomomi Nakamura, Rieko Sakamoto, Takeshi Inoue, Kenichi Tanaka, Shirou Matsumoto, Kimitoshi Nakamura, Hiroshi Mitsubuchi

Summary: This study investigated the relationship between serum procalcitonin (PCT) and C-reactive protein (CRP) levels and the severity of postnatal respiratory conditions in preterm neonates. The results showed that serum PCT levels were associated with the severity of respiratory conditions in preterm neonates.

PEDIATRIC PULMONOLOGY (2022)

Editorial Material Pediatrics

Severe metabolic acidosis with cardiac involvement in DNM1L-related mitochondrial encephalopathy

Yuya Kinoshita, Ken Momosaki, Shirou Matsumoto, Kei Murayama, Kimitoshi Nakamura

PEDIATRICS INTERNATIONAL (2022)

Article Immunology

Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination

Yusuke Miyashita, Takanobu Yoshida, Yuriko Takagi, Hirotake Tsukamoto, Ken Takashima, Takahisa Kouwaki, Katsunari Makino, Satoshi Fukushima, Kimitoshi Nakamura, Hiroyuki Oshiumi

Summary: The study found that EV miR-92a-2-5p levels in serum were negatively correlated with adverse reactions after COVID-19 vaccination, while EV miR-148a levels were associated with specific antibody titers. This suggests that circulating EV miRNAs could serve as biomarkers for vaccine efficacy and adverse reactions.

NPJ VACCINES (2022)

Article Biology

TICAM-1/TRIF associates with Act1 and suppresses IL-17 receptor-mediated inflammatory responses

Yusuke Miyashita, Takahisa Kouwaki, Hirotake Tsukamoto, Masaaki Okamoto, Kimitoshi Nakamura, Hiroyuki Oshiumi

Summary: TICAM-1 acts as a negative regulator in IL-17A-mediated inflammatory responses by inhibiting the interaction between IL-17RA and Act1.

LIFE SCIENCE ALLIANCE (2022)

Article Clinical Neurology

Muscle biochemical and pathological diagnosis in Pompe disease

Yoshihiko Saito, Kimitoshi Nakamura, Tokiko Fukuda, Hideo Sugie, Shinichiro Hayashi, Satoru Noguchi, Ichizo Nishino

Summary: This study investigated the prevalence of Pompe disease in Japan and concluded that it is less prevalent compared to neighboring countries. Muscle biopsy was found to be an accurate method for diagnosing the disease.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Article Hematology

Screening for Fabry disease among male patients on hemodialysis in Awaji Island

Mao Shimizu, Hideki Fujii, Keiji Kono, Kentaro Watanabe, Shunsuke Goto, Kandai Nozu, Kimitoshi Nakamura, Shinichi Nishi

Summary: This study did not identify any Fabry disease patients among male hemodialysis patients in Awaji Island, Japan, despite some patients having a family history of kidney and cardiovascular diseases. Although a few patients had low levels of alpha-galactosidase A activity, none of them tested positive in secondary screening.

THERAPEUTIC APHERESIS AND DIALYSIS (2022)

Article Genetics & Heredity

Newborn screening for Gaucher disease in Japan

Takaaki Sawada, Jun Kido, Keishin Sugawara, Shinichiro Yoshida, Shirou Matsumoto, Tomoyuki Shimazu, Yuki Matsushita, Takahito Inoue, Shinichi Hirose, Fumio Endo, Kimitoshi Nakamura

Summary: Gaucher disease is a genetic disorder classified into three types, with limited treatment options, especially for neurological symptoms. Japan has a higher number of patients with neurological symptoms, but newborn screening is not widely performed. The frequency of GD diagnosis through NBS is higher than previously estimated in Japan, and the future of NBS for GD in Japan looks promising.

MOLECULAR GENETICS AND METABOLISM REPORTS (2022)

Article Pediatrics

The Predictive Value of Procalcitonin and High-Sensitivity C-Reactive Protein for Early Bacterial Infections in Preterm Neonates

Tetsuo Naramura, Hiroko Imamura, Hidetaka Yoshimatsu, Kaname Hirashima, Shinji Irie, Takeshi Inoue, Kenichi Tanaka, Hiroshi Mitsubuchi, Kimitoshi Nakamura, Masanori Iwai

Summary: This study found that serum procalcitonin levels in preterm neonates are influenced by respiratory failure, and have a better predictive value for bacterial infections compared to high-sensitivity C-reactive protein.

NEONATOLOGY (2021)

No Data Available